Midatech Pharma PLC (LON:MTPH)

Midatech Pharma PLC (LON:MTPH)

Share Price
5.59 p
-0.06 (-1.06 %)
Market Cap
£22.89 m
Proactive Investors - Run By Investors For Investors

Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.


Market: AIM:MTPH
52-week High/Low: 39.20p / 2.45p
Sector: Pharmaceuticals
Market Cap: £22.89 m
Website: www.midatechpharma.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Midatech Pharma PLC

Midatech Pharma PLC Snapshot

Midatech’s strategy is to expand its US commercial presence as well as develop its platform technologies into multiple products in order to achieve multiple potential revenue opportunities. Its business model has three key components:

Development and commercialisation of its own products, particularly for rare cancers

Development and commercialisation of partner-supported and licensed products, principally in endocrine disorders such as diabetes, and immunotherapy for autoimmune diseases

Acquisitions of later stage, strategic and complementary opportunities (products or technologies) that accelerate revenue, and are value accretive

Its commercialisation strategy is to build an enduring, profitable and commercially focused enterprise with revenues generated as follows:

Research and development collaborations

Partner licensing and royalty deals

Commercialisation of own products in the specialist orphan sector

In oncology, Midatech has the opportunity to leverage its own commercial capabilities in the US and roll out similar infrastructure in Europe around the market entry of its orphan oncology program products.


Versatile technology platforms with broad applications across multiple therapeutic areas.

Central to Midatech’s business are two platform technologies that are designed to enable the targeted delivery (‘right place’) and controlled release (‘right time’) of existing drugs. These technologies have broad applications in multiple therapeutic areas and will allow Midatech to develop multiple revenue streams.

GNP Technology

Midatech’s primary platform technology is based on carbohydrate-coated gold nanoparticle (GNP) drug conjugates.



Midatech’s core technology platform is based on a patented form of gold nanoparticles (GNPs), which has been developed to improve key parameters when bound to existing and new drugs. GNPs aim to target individual cell types with specific targeting agents and deliver a therapeutic payload into the tumour cell, and reduce the current side-effect profile associated with chemotherapy. GNP technology is the latest generation of nanomedicine, with demonstrated safety in the clinic to date.

The key advantages of Midatech’s GNP platform technology are:

  • Solubility: Can bind and transport non-soluble and lipid soluble therapeutic compounds to sites of disease
  • Releasability: GNP-drug conjugates can release the active compound inside the cell
  • Mobility: Small size (3.5 nanometer diameter) means GNP-drug conjugates may cross membranes (including the blood brain barrier), move between cells and through cells to reach diseased cells
  • Targetability: Multiple binding sites mean several therapeutics and targeting agents may be attached to a single nanoparticle
  • Stability: Peptides may be stabilised by GNP drug conjugates as they have less freedom to degrade when bound
  • Excretability: Due to their small size, GNP drug conjugates are believed to exit cells and get eliminated via the kidneys and liver
  • Compatibility: GNPs are inert and biocompatible, and are not expected to trigger an immune response
  • Scalability: Through its own GMP manufacturing facility, Midatech can control the supply and develop quality material for clinical trials and commercialisation

For more information, please click here

Sustained Release

Midatech’s sustained release technology platform (“Q-Sphera”) may enable active drug compounds to be manufactured with consistent precision and released into the body in a highly controlled manner over a prolonged period of time: potentially from a few days to up to six months.

The potential advantages of the sustained release drug delivery system over conventional dosage forms include:

  • Improved patient compliance: due to less frequent drug administration
  • Reduction of fluctuation in steady-state drug levels
  • Maximum use of the drug
  • Increased safety margin
  • Reduction in healthcare costs through improved therapy

Midatech’s Q-Sphera polymer microsphere platform is being developed to enable sustained release delivery solutions for peptide and small-molecule therapeutics through precise definition of the properties of polymer microparticles into which compounds can be incorporated. Microspheres are small, spherical particles that can be utilised as a time release drug capsule.

Midatech's Q-Sphera micro-fluidic technology allows the precise formulation and characterisation of the release of drugs over a predefined period from a few days up to three months. The manufacturing technology allows particles to be engineered with high precision and consistent size, alongside other key characteristics.

Q-Sphera can use a wide range of biomaterials to encapsulate drug candidates into micron sized particles (of diameter ~25μm). Long-acting treatment is achieved using formulations of biodegradable polymers (including polylactides) to control the release of API over a period of 3-6 months following a single injection. Monodisperse microspheres may be readily injected via minimally-invasive needles as fine as 30G. In formulating small molecules, biopharmaceuticals and PEGylated species, Midatech focuses on developing products that provide high drug loading, with minimal initial burst release, which is essential to the development of safe and effective therapies. This requires precise control over particle size, morphology and drug kinetics. This Midatech microsphere manufacturing enables emulsion-free synthesis with both product monodispersity and processing efficiency.

Markets of focus for such preparations include oncology, immunology, endocrinology, neuroscience, and ophthalmology. Sustained release programs are underway in:

Oncology and Endocrinology/ Q-Octreotide—a lead program in acromegaly, an endocrine disorder in which the body produces too much growth hormone, and a second programme in carcinoid syndrome, an oncologic disorder of neuro-endocrine tumours; and
Ophthalmology/ Opsisporin—in uveitis (inflammation of the eye).


Midatech operates an in-house nanoparticle manufacturing facility, which is believed to be the first licensed API cGMP facility of its kind in Europe. This state-of-the-art facility based in Bilbao, Spain, aids in the rapid execution of projects, control of manufacturing quality and supply of all aspects of Midatech’s GNP platform, thus avoiding reliance on external manufacturing partners.

The site has capacity for manufacturing sufficient materials for clinical trials and is fully licensed by the Spanish Medicines Agency for European compliance. The facility underwent a €800,000 upgrade in September 2014 to enable the production of sterile material for use in human clinical trials and initial phase manufacturing of licensed product.

Also in 2014, an international consortium led by Midatech was selected to receive a €7.9 million Horizon 2020 European Union “NanoFacturing” grant to fund the manufacturing scale-up of clinical-grade therapeutics based on its GNP drug conjugate technology and other nanopharmaceuticals, for use in clinical trials and in preparation for commercial production and supply. Midatech is also able to leverage this facility to manufacture for other non-competing nanomedicine businesses, representing additional revenue - generating opportunities. The Horizon 2020 grant submission was supported by Eli Lilly.

Further investment in commercial scale up of production is on-going at Midatech Bilbao facility. This will enable Midatech to capture more of the integrated value chain and manufacture in-house Q-Octreotide and other projects.



Midatech's two platform technologies are designed to enable targeted delivery and sustained release respectively of existing therapeutic drugs to the ‘right place’ at the ‘right time’. The first of these platforms is a Gold Nanoparticle Technology Platform (GNPs) that are developed to improve key parameters of existing and new drugs, target individual cell types with specific targeting agents and deliver a payload in the cell, while ensuring this can be achieved safely. GNP technology represents amongst the latest generation of nanomedicine and the fastest growing sector within the nanomedicine market. The second of these platforms is a Microsphere Sustained Release Technology Platform (SR) that achieves consistent and precise encapsulation of active drug compounds within polymer microspheres. The microspheres are designed to release the active drug compound into the body in a highly controlled manner over a prolonged period of time, from a number of weeks to six months and potentially longer. Sustained release technology provides the added capacity to sustain the optimal range of drug concentrations, which has wide medical applicability with diverse pharmaceutically active molecules.

For information on Oncology, please click here

For information on Autoimmune Diseases, please click here

To view the pipeline of products, please click here

For  more information on Q-Octreotide, please click here

For more information on Opsisporin, please click here

For more information on HCC, please click here

For more information on Glioblastoma (GBM), please click here

For more information on Diabetes Vaccine, please click here



Dr Jim Phillips, MB, ChB, MBA
Chief Executive Officer

Dr Phillips has a strong background in company leadership and business development, and is a physician by training. He founded Talisker Pharma in 2004, which was the first and cornerstone acquisition of EUSA Pharma in 2006. As President of Europe and Senior Vice President, Corporate Development of EUSA Pharma Inc., Dr Phillips led the strategy resulting in the acquisition of OPI and its ultimate acquisition by Jazz Pharmaceuticals in 2012. Dr Phillips is currently a Non-executive Director of Herantis Pharma plc (listed in Helsinki) and Preci-Health SA (a private medical technology business).  He was formerly a Non-executive Director of Insense Ltd (a private spin-out from Unilever), and, until joining Midatech, was Chairman of Prosonix Limited, guiding its successful transformation into a respiratory focused business.

Dr Phillips initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, he was in Clinical & Business Development and was a Board Director of the $1.3bn Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit and a member of the company’s Clinical Leadership Team.

Dr Jim Phillips has been awarded “Best CEO-Pharmaceuticals Industry” for 2015.


Nick Robbins-Cherry, ACA, MBA
Chief Financial Officer


Dr Craig Cook, MD, MBA
Chief Operating Officer / Chief Medical Officer
Chief Executive Officer Designate


Dr Steve Damment, Ph.D.
Head of Research and Development


Rob Rainey, FCA MBA MA
Head of Corporate Development


David Benharris
President, Midatech Pharma US, Inc.
Name Number of shares %
Woodford Investment Management 12,247,629 20.1
Legal & General Group


City Financial 3,650,000 6.0
Wings Establishment 3,043,164 5.0
Hargreave Hale 2,992,585 4.9
Midatech Pharma Share Incentive Plan 105,068 n/a


Midatech Pharma Plc

65 Innovation Drive

Milton Park


Oxfordshire OX14 4RQ

United Kingdom

T: +44 (0)1235 888300
E: [email protected]

Nominated Adviser and Broker
Panmure Gordon (UK) Limited
One New Change
United Kingdom
+44 (0)20 7886 2500

Financial Public Relations & Investor Relations (UK)
Consilium Strategic Communications (City, trade, institutions and financial media enquiries)
41 Lothbury
London EC2R 7HG
United Kingdom
+44 (0)20 3709 5700
[email protected]

Cassiopeia Services (Private investors and general media enquiries)
55 Gower Street
London WC1E6HQ
United Kingdom
[email protected]

Investor Relations (US)

Westwicke Partners, Boston, US
132 Chief Justice Cushing Highway
Cohasset, MA 02025 | (339) 970-2843Solicitors


Brown Rudnick LLP
8 Clifford Street
London W1S 2LQ
United Kingdom

Reporting Accountants and Auditors

55 Baker Street
London W1U 7EU
United Kingdom


Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen B63 3DA
United Kingdom

Columns Including MTPH


Market Reports Including MTPH

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use